A subchronic toxicity study of Phosflex 51B in Sprague-Dawley rats.
Phosflex 51B is a flame retardant plasticizer that is blended with polyvinyl chloride films to effectively control product flammability. Its composition places it in the butylated triphenyl phosphate category. Previous studies have shown Phosflex 51B to have low acute toxicity, to lack teratogenic and mutagenic activity, and to not induce delayed peripheral neuropathy. The present study was conducted to determine the toxicity of Phosflex 51B after repeated dietary exposure. Four groups, each consisting of 20 male and 20 female Sprague-Dawley rats, received rodent diet containing either 0, 100, 400, or 1600 ppm for 90 days. Parameters measured include body weight, food consumption, clinical observations, hematology, clinical chemistry, and cholinesterase activity. Tissues were examined at necropsy for gross changes and were processed for microscopic pathology. There were no significant treatment-related effects on body weights, food consumption, hematology and clinical chemistry, or cholinesterase values. A significant increase was observed in the absolute and relative mean weights of livers in high-dose male rats, the mean relative liver weights of the high-dose female animals, the mean relative kidney weights of the high-dose male rats, and the mean absolute weights of the adrenal glands from high-dose female rats. Neither gross nor microscopic pathology examinations revealed tissue changes in these organs or in any other organs. Although increases in liver, kidney, and adrenal weights were observed in certain animals in the 1600-ppm high-dose group, the administration of Phosflex 51B did not result in significant treatment-related adverse effects at dietary dose levels of 100 and 400 ppm. The no-observable-effect level (NOEL) in this study is 400 ppm.
Freudenthal
R I
RI
Akzo Nobel Chemicals Inc., Dobbs Ferry, New York, USA.
Brandwene
D
D
Clous
W
W
D000311:Adrenal Glands / Q000473:pathology; D000818:Animals; D001774:Blood Chemical Analysis; D001835:Body Weight / Q000187:drug effects; D002802:Cholinesterases / Q000378:metabolism; D004032:Diet; D005260:Female; D005411:Flame Retardants / Q000633:toxicity*; D015386:Hazardous Substances / Q000633:toxicity; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D008297:Male; D008853:Microscopy; D019055:No-Observed-Adverse-Effect Level; D009929:Organ Size / Q000187:drug effects; D010755:Organophosphates / Q000097:blood / Q000633:toxicity* / Q000652:urine; D010968:Plasticizers / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley
D005411:Flame Retardants; D015386:Hazardous Substances; D010755:Organophosphates; D010968:Plasticizers; C025742:dibutyl phenylphosphate; D002802:Cholinesterases; C005445:triphenyl phosphate